Oligonucleotide Therapeutics Society
OTS is a forum to foster academic and industry-based research and development of oligonucleotide therapeutics.
Nordic Digital Science & Innovation Day
Sharing the latest trends, innovations, and best practices for digitizing R&D assets to accelerate modern science.
Reducing R&D risk for top-10 pharmaceutical company
Our explainable models yielded a 44 percentage point improvement in catching toxic drugs in the drug development pipeline
siRNA molecule activity: explainable AI models uncover underlying mechanisms
Our results-driven world pressures us to give up good science.
Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases using xAI technology
According to recent research in European Journal of Human Genetics, there are more than 6.000 rare diseases affecting more than 300 million people world-wide. Today, only 450 FDA-approved orphan drug products are available, which leaves hundreds of millions suffering from chronic diseases and at risk of early death. Nucleic acid-based medicine (NABM), also known as RNA therapeutics, is […]
AI and nucleic acid-based medicine: can symbolic regression unite them?
How the QLattice explains the cellular toxicity of RNA-targeting drugs.